9UA Stock Chart & Stats
€1.38
-€0.05(-3.50%)
At close: 4:00 PM EDT
€1.38
-€0.05(-3.50%)
Day’s Range― - ―
52-Week Range€1.33 - €5.00
Previous CloseN/A
Volume0.00
Average Volume (3M)821.00
Market Cap
€115.46M
Enterprise Value€289.36
Total Cash (Recent Filing)€16.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 12, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding82,193,140
10 Day Avg. Volume1,284
30 Day Avg. Volume821
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.96Price Target Upside549.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt materially reduces financial distress risk for a clinical-stage biotech that requires external funding. Low leverage preserves flexibility to prioritize equity financing or partnership deals over costly interest-bearing debt, supporting continuity of R&D spending through development milestones.
Objective Efficacy Signal And Regulatory AlignmentIndependently blinded gait analyses showed statistically significant, multi-domain neural recovery signals and the company secured FDA End-of-Phase 2 alignment for a registrational RESTORE Phase 3. This de-risks the lead program structurally and strengthens the path to potential approval and commercialization.
Access To Capital MarketsA successful $60M underwritten raise demonstrates institutional capital-market support and meaningfully extends the company's clinical development runway. Reliable access to financing is a durable operational enabler for executing costly late-stage trials and advancing registrational plans.
Bears Say
Pre-Revenue With Rising Cash BurnThe company is pre-revenue with widening losses and materially negative operating cash flow, which structurally necessitates continued external funding. Persistent burn without commercial cash generation increases execution risk for multi-year Phase 3 programs and heightens dilution risk for stakeholders.
Dependence On Equity Financing And DilutionFrequent equity raises, including an at-the-market facility and recent underwritten offering with warrants, indicate structural reliance on issuing shares to fund operations. That dependence produces recurring dilution, can complicate long-term ownership incentives, and ties program continuity to market access.
Modest Cash Reserves And Asset BaseRelatively small cash balances and modest total assets constrain flexibility to absorb trial delays or cost overruns. Given high and rising burn, limited reserves raise the likelihood of additional financings before pivotal readouts, creating execution risk and potential pressure on program timelines.
NervGen Pharma News
9UA FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was €1.33 and its highest was €5.00 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is €115.46M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.
How were NervGen Pharma’s earnings last quarter?
Currently, no data Available
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.05.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 82,193,140 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in DE:9UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.96 (549.06% Upside)
€8.96 (549.06% Upside)
Blogger Sentiment
Bullish
DE:9UA Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.21%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
9UA Stock 12 Month Forecast
Average Price Target
€8.96
▲(549.06% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―